Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Anemia is a frequent cytopenia in myelodysplastic syndromes (MDS) and most patients require red blood cell transfusion resulting in iron overload (IO). Deferasirox (DFX) has become the standard treatment of IO in MDS and it displays positive effects on erythropoiesis. In low risk MDS samples, mechan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Meunier, Mathieu, Ancelet, Sarah, Lefebvre, Christine, Arnaud, Josiane, Garrel, Catherine, Pezet, Mylène, Wang, Yan, Faure, Patrice, Szymanski, Gautier, Duployez, Nicolas, Preudhomme, Claude, Biard, Denis, Polack, Benoit, Cahn, Jean-Yves, Moulis, Jean Marc, Park, Sophie
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739655/
https://ncbi.nlm.nih.gov/pubmed/29285268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22299
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados